Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

#3550

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Aim(s): To compare the progression-free survival (PFS) rate at 12 months between everolimus or chemotherapy administered frontline. Secondary endpoints include response rate, PFS1, PFS2, overall survival, safety, and health economics data.

Materials and methods: Patients with advanced WHO grade 1/2 panNETs were randomized 1:1 to everolimus 10 mg/day followed by STZ-5FU upon progression (Arm A) or the reverse sequence (Arm B). STZ-5FU was administered according to Moertel or Uppsala regimens.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,